

Press release

Susanne Resatz, President of Vetter Development Services USA, Inc. is elected to the board of directors of the German American Chamber of Commerce® of the Midwest, Inc.

Skokie, USA, and Ravensburg, Germany, April 12, 2016 – The German American Chamber of Commerce® of the Midwest, Inc., (GACC Midwest) elected Susanne Resatz, Ph.D., President of Vetter Development Services USA, Chicago in March as a member of its board of directors. The goal of the organization, of which Vetter has been a member since 2010, is to further promote and assist in the expansion of bilateral trade and investment between the United States, especially the Midwest, and Germany. This is supported by a diverse mix of board members, representing various aspects of industry, company size, and business function. GACC Midwest’s territory covers 14 US states: the 13 states of the Midwest and Colorado, comprising together approximately one quarter of the nation’s geographical area, its population, and its gross domestic product. With almost 1,400 German businesses operating in the Midwest, the region represents a dynamic business location, particularly for transatlantic trade.

“I am very happy to be elected to the board of GACC Midwest. This organization also represents the very essence of what Vetter has been working to create as a company, which is being a leading service provider – for us, achieving this, for example, through our manufacturing footprint in both the US and Germany. The ‘two-country’ manufacturing positioning affords us valuable opportunity to efficiently supply our (bio-)pharmaceutical customers in these two countries, and also those located in other areas in the world,” said Dr. Resatz. GACC Midwest connects business partners, provides insights on industry best practices, works to create skilled workforce models, and enables a knowledge exchange between peers. The diverse membership profile of GACC Midwest – including various business, industry and services sectors provides a promising ground for cross-fertilization. “Actively participating in organizations such as GACC Midwest helps Vetter broaden its horizon, with the goal of contributing to innovative and foresighted business and manufacturing processes. As such, they are instrumental in helping to strengthen our relationships with customers, suppliers, and other stakeholders.”

Dr. Resatz – a pioneer in Vetter’s Chicago site

Dr. Resatz has headed up Vetter’s Chicago clinical manufacturing facility since 2014. She earned a Master’s Degree with a major in Applied Mathematics from Vienna University of Technology in 2002, and a Doctoral degree in the field of Computational Neuroscience and Biomedical Engineering from Vienna University of Technology in 2005. Dr. Resatz relocated from Germany to the United States in 2010, and was among the first employees to help establish Vetter Development Services USA, Inc., located at the Illinois Science + Technology Park in Skokie, Illinois. Dr. Resatz began her career at Vetter in 2006 in the position of Process Implementation Specialist. Prior to her move to Chicago, she worked on high level process implementation projects within Vetter. Her specialized knowledge of Vetter’s services, equipment and techniques has led to numerous collaborations with (bio-)pharmaceutical companies from around the world.

Vetter’s Chicago facility is the company’s US clinical manufacturing site, providing development support for preclinical through phase II injectables, primarily complex biologics. The site offers all the resources needed for efficient early-stage clinical manufacturing, including chemical analysis and microbiology labs, material preparation and compounding functions. At the heart of the facility are its cleanrooms, followed by visual inspection capabilities and GMP storage. The facility currently operates with a growing staff of more than 60, and has collaborated with (bio-)pharmaceutical clients from the US, as well as Europe, Asia, and the Middle East, with treatments under development for cancer, muscular dystrophy, dwarfism and other conditions. Once the early clinical development phases are completed, the customer product can be transferred to the company’s German facilities for manufacturing of late-stage clinical supply and for subsequent commercial production.



Dr. Susanne Resatz, Ph.D., President of Vetter Development Services USA, Inc. is a new board member of the GACC Midwest.

About Vetter

Vetter is a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with production facilities in Germany and the United States, the contract development and manufacturing organization (CDMO) is an innovative solution provider serving the top 10 (bio-)pharmaceutical companies, as well as small and midsize companies. Its portfolio spans state-of-the-art manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. The company's extensive experience covers a broad range of complex compounds including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company of approximately 3,600 employees offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. The CDMO is also committed to patient safety and compliance with user friendly solutions such as Vetter-Ject[®], as well as its dual-chamber syringe Vetter Lyo-Ject[®] and cartridge system V-LK[®]. Vetter's branch office in Singapore and its subsidiary in Tokyo, Japan, increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com.

Contact

Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com